BACKGROUND: Metabolic and inflammatory disturbances associated with obesity are considered important trigger factors for venous thromboembolism (VTE). Identification of clinical markers indicating a hypercoagulability state could define a group of high-risk patients in the surgical setting. This study aimed to identify these markers using rotational thrombelastometry (ROTEM) analysis, an established method for hemostasis testing that can detect hyperfunctional stages of the clotting process. METHODS: From June to December 2010, this study investigated 109 consecutive obese patients (28 women and 22 men, mean age 46 years, body mass index 46.6 ± 7 kg/m(2)) with no history of VTE who were candidates for bariatric surgery. Preoperative clinical and metabolic characteristics and ROTEM analysis were recorded. Hypercoagulable risk was defined when patients showed a clot strength (G) of ≥11 dynes/cm(2). RESULTS: Of the 109 patients, 20 (18%) were hypercoagulable according to ROTEM analysis. Metabolic/inflammatory biomarkers such as leptin, C-reactive protein, fibrinogen levels, and platelet count were significantly higher in the high-risk patients. In the multivariate analysis, fibrinogen was an independent predictor of G ≥ 11 dynes/cm(2) [odds ratio (OR) 2.92, 95 % confidence interval (CI) 1.80-5.21, p = 0.023]. After adjustment to other data, only waist circumference affected the prediction [OR 4.42, 95 % CI 2.27-6.71, p = 0.009]. Receiver operating characteristic curve analysis showed that 3.95 g/l was the best cutoff point for fibrinogen predictability (sensitivity 100 %, specificity 41%). CONCLUSION: A hypercoagulability state in obese patients is associated with central obesity and high fibrinogen levels, which should be considered clinical hallmarks of this state. More aggressive perioperative prophylaxis for VTE should be recommended when these hallmarks are present in obese patients.
BACKGROUND: Metabolic and inflammatory disturbances associated with obesity are considered important trigger factors for venous thromboembolism (VTE). Identification of clinical markers indicating a hypercoagulability state could define a group of high-risk patients in the surgical setting. This study aimed to identify these markers using rotational thrombelastometry (ROTEM) analysis, an established method for hemostasis testing that can detect hyperfunctional stages of the clotting process. METHODS: From June to December 2010, this study investigated 109 consecutive obesepatients (28 women and 22 men, mean age 46 years, body mass index 46.6 ± 7 kg/m(2)) with no history of VTE who were candidates for bariatric surgery. Preoperative clinical and metabolic characteristics and ROTEM analysis were recorded. Hypercoagulable risk was defined when patients showed a clot strength (G) of ≥11 dynes/cm(2). RESULTS: Of the 109 patients, 20 (18%) were hypercoagulable according to ROTEM analysis. Metabolic/inflammatory biomarkers such as leptin, C-reactive protein, fibrinogen levels, and platelet count were significantly higher in the high-risk patients. In the multivariate analysis, fibrinogen was an independent predictor of G ≥ 11 dynes/cm(2) [odds ratio (OR) 2.92, 95 % confidence interval (CI) 1.80-5.21, p = 0.023]. After adjustment to other data, only waist circumference affected the prediction [OR 4.42, 95 % CI 2.27-6.71, p = 0.009]. Receiver operating characteristic curve analysis showed that 3.95 g/l was the best cutoff point for fibrinogen predictability (sensitivity 100 %, specificity 41%). CONCLUSION: A hypercoagulability state in obesepatients is associated with central obesity and high fibrinogen levels, which should be considered clinical hallmarks of this state. More aggressive perioperative prophylaxis for VTE should be recommended when these hallmarks are present in obesepatients.
Authors: Hanneke J B H Beijers; Isabel Ferreira; Henri M H Spronk; Bert Bravenboer; Jacqueline M Dekker; Giel Nijpels; Hugo ten Cate; Coen D A Stehouwer Journal: Arterioscler Thromb Vasc Biol Date: 2010-09-16 Impact factor: 8.311
Authors: Jeffry L Kashuk; Ernest E Moore; Allison Sabel; Carlton Barnett; James Haenel; Tuan Le; Michael Pezold; Jerry Lawrence; Walter L Biffl; C Clay Cothren; Jeffrey L Johnson Journal: Surgery Date: 2009-10 Impact factor: 3.982
Authors: D Wayne Overby; Geoffrey P Kohn; Mitchell A Cahan; Joseph A Galanko; Karen Colton; Stephan Moll; Timothy M Farrell Journal: Obes Surg Date: 2009-07-05 Impact factor: 4.129
Authors: Ronald H Clements; Kishore Yellumahanthi; Naveen Ballem; Mary Wesley; Kirby I Bland Journal: J Am Coll Surg Date: 2009-05 Impact factor: 6.113
Authors: Bryce A Kerlin; Amanda P Waller; Ruchika Sharma; Melinda A Chanley; Marvin T Nieman; William E Smoyer Journal: J Am Soc Nephrol Date: 2015-04-08 Impact factor: 10.121
Authors: Matthew B A Harmon; Nanon F L Heijnen; Sanne de Bruin; Niek H Sperna Weiland; Joost C M Meijers; Anita M de Boer; Marcus J Schultz; Janneke Horn; Nicole P Juffermans Journal: Br J Anaesth Date: 2021-04-23 Impact factor: 9.166
Authors: Marcella C A Müller; Kirsten Balvers; Jan M Binnekade; Nicola Curry; Simon Stanworth; Christine Gaarder; Knut M Kolstadbraaten; Claire Rourke; Karim Brohi; J Carel Goslings; Nicole P Juffermans Journal: Crit Care Date: 2014-12-25 Impact factor: 9.097